Nutrition and Metabolic Prehabilitation in HSCT Patients UK and ROI. BSBMT Multi-centre Survey.

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

66 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-08-01

Study Completion Date

2022-03-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To explore current practices of nutrition and metabolic screening, assessment and management prior to Haematopoietic Stem Cell Transplant (HSCT) in UK and ROI transplant centres.

Nutrition and metabolic parameters assessed in the survey include glycaemic control, lipid function, liver function, nutritional screening, nutritional assessment, nutrition intervention (tube feeding, diet, micronutrient) and exercise.

This work will be used to inform the design of a UK dual centre feasibility study of personalised nutrition and metabolic care for HSCT patients prior to transplantation.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Nutritional Status of Patients After Hematopoietic Stem Cell Transplantation

NCT04146870

Nutrition Hematopoietic Stem Cell Transplantation

RECRUITING

UF-BMT-HSCT-001: A Non-Interventional Study Evaluating Diet in HSCT Survivors

NCT03377010

Hematopoietic Neoplasm

COMPLETED

Evolution of the Energy Expenditure During Hematopoietic Stem Cell Transplantation

NCT04535570

Bone Marrow Transplantation Hematopoietic Stem Cell Transplantation

COMPLETED

Musculoskeletal Outcomes After Bone Marrow Transplant

NCT00558948

Survivors of Bone Marrow Transplant Autologous and Allogeneic

COMPLETED

Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell Transplantation

NCT02598752

Acute Myeloid Leukemia Myelodysplastic Syndrome Hematological Malignancy +3 more

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Haematological Malignancy Bone Marrow Transplant Complications Stem Cell Transplant Complications Nutrition Aspect of Cancer Nutritional and Metabolic Disease Exercise Interventions Prehabilitation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Non validated Survey

Overall inclusion of metabolic and nutritional parameters in prehabilitation practices will be assessed as the proportion of each parameter conducted from the mandatory queries presents as yes/no/unsure responses for each centre. Intervention or process details for included parameters will be described based on the response variable. The survey presents 4 question formats; free text (thematic qualitative analysis), 5 and 6 point likert scales (proportional response), categorical data (proportional response) and yes/no/unsure response sets (Binary response (no and unsure - grouped). All categorical data versions are parameter dependent and response variables can be requested from the research team.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* BSBMT registered adult HSCT centres (including TYA services where patients have opted to be treated in an adult service pathways)
* Centres delivering either autologous or allogeneic stem cell transplants